Pure Global
NCT06366802

Cohort Construction and Prognostic Model Construction for Multiple Myeloma

The First Affiliated Hospital of Soochow University·ClinicalTrials.govRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Study type
Observational
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Soochow University
Location
Suzhou, China
Timeline & enrollment
Phase
N/A
Start date
May 03, 2022
End date
May 02, 2027
Enrollment
1000 participants
Primary outcome

Overall survival

Summary

Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder.
 Survival outcomes continue to vary widely even within uniformly treated clinical trial
 populations. How to construct a clinical prognosis model of MM through real-world data to
 guide the selection of treatment options, standardize patient management, and improve
 survival expectations, is a major problem that needs to be solved urgently. It is necessary
 to build an MM-specific cohort in China to comprehensively understand the characteristics of
 MM patients, explore treatment options, and improve prognostic factors for survival outcomes.

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06366802
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06366802 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital of Soochow University and is currently Recruitment Completed. The study focuses on Multiple Myeloma. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.